
Biomednewsbreaks - Kairos Pharma Ltd. (NYSE American: KAPA) Secures Dod Grant To Advance Lung Cancer Biomarker Research
(MENAFN- Investor Brand Network) Kairos Pharma (NYSE American: KAPA) announced that the U.S. Department of Defense has awarded $876,000 to Cedars-Sinai Medical Center to support biomarker research for Kairos' Phase 1 trial of ENV105 in EGFR-driven non- …